The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1471
ISSUE 1471
June 22, 2015
Issue 1471
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Liraglutide (Saxenda) for Weight Loss
June 22, 2015 (Issue: 1471)
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist liraglutide, previously approved by the
FDA for treatment of type 2 diabetes as Victoza, has
now also been approved at a higher dose as Saxenda
(Novo Nordisk) for chronic weight...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.